Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andromachi Reklou

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Vascular Pharmacology|January 22, 2019
Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?Andromachi Reklou, Niki Katsiki, Asterios Karagiannis, et al.
Current Pharmaceutical Design|October 16, 2018
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 InhibitorsEleni Theocharidou, Marianna Papademetriou, Andromachi Reklou, et al.
The Open Cardiovascular Medicine Journal|May 23, 2018
Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?Andromachi Reklou, Michael Doumas, Konstantinos Imprialos, et al.
Current Pharmaceutical Design|June 6, 2018
Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard EndpointsMichael Doumas, Κonstantinos Imprialos, Konstantinos Stavropoulos, et al.
Case Reports in Obstetrics and Gynecology|April 4, 2015
Dealing with Pheochromocytoma during the First Trimester of PregnancyKonstantinos Kiroplastis, Apostolos Kambaroudis, Apostolos Andronikou, et al.
Biomedicines|September 28, 2024
Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory StudyDimitrios Kouroupis, Ioanna Zografou, Aikaterini Balaska, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Vascular Pharmacology|January 22, 2019
Effects of Lipid Lowering Drugs on Arterial Stiffness: One More Way to Reduce Cardiovascular Risk?Andromachi Reklou, Niki Katsiki, Asterios Karagiannis, et al.
Current Pharmaceutical Design|October 16, 2018
The Role of PCSK9 in the Pathogenesis of Non-alcoholic Fatty Liver Disease and the Effect of PCSK9 InhibitorsEleni Theocharidou, Marianna Papademetriou, Andromachi Reklou, et al.
The Open Cardiovascular Medicine Journal|May 23, 2018
Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?Andromachi Reklou, Michael Doumas, Konstantinos Imprialos, et al.
Current Pharmaceutical Design|June 6, 2018
Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard EndpointsMichael Doumas, Κonstantinos Imprialos, Konstantinos Stavropoulos, et al.
Case Reports in Obstetrics and Gynecology|April 4, 2015
Dealing with Pheochromocytoma during the First Trimester of PregnancyKonstantinos Kiroplastis, Apostolos Kambaroudis, Apostolos Andronikou, et al.
Biomedicines|September 28, 2024
Presepsin Levels in Infection-Free Subjects with Diabetes Mellitus: An Exploratory StudyDimitrios Kouroupis, Ioanna Zografou, Aikaterini Balaska, et al.
Pageof 1